NewsBite

Pharmaceuticals

Yesterday

Person with pill.

People are taking a pill to extend their lives. Will it work?

Rapamycin is typically prescribed as an immunosuppressive, but off-label users believe it can do much more.

  • Dana Smith

September

Models walk the runway as part of Paris Fashion Week.

Everyone’s on Ozempic, so why won’t anyone ‘admit’ it?

The fashion world is embracing weight-loss drugs – but very discreetly.

  • Jo Ellison
Adam Steensberg: “Obesity is the biggest healthcare challenge of our time.”

The doctor-turned-CEO aiming to beat Ozempic

Adam Steensberg leads Zealand Pharma, a Danish drug maker whose stock has risen by more than 800 per cent since he took over in 2022.

  • Sara Sjolin
BlackRock will look to acquire existing research laboratories.

BlackRock seeds $1.5b laboratory real estate fund

BlackRock is partnering with local private equity firm Wentworth Capital on a “pure play” laboratory fund that has already secured a number of seed assets

  • Larry Schlesinger
Vikesh Ramsunder, CEO of Sigma Healthcare, expects the ACCC to make a call on its merger with Chemist Warehouse on October 24.

ACCC call on Sigma, Chemist Warehouse $8.8b tie-up due in four weeks

Merger plans are tracking in line with expectations, with the competition watchdog to make a final decision on October 24 after a previous delay.

  • Carrie LaFrenz
Advertisement
Telix CEO Christian Behrenbruch has upgraded 2024 revenue forecasts.

Telix on $1b spending spree to build US radiopharmacy network

The biotech is investing heavily in global networks that will enable it to control the supply and distribution of nuclear medicines used to treat cancer.

  • Michael Smith
Pharma companies say they need help developing new antibiotics are needed to fight superbugs.

Why big pharma wants the government to pay it to make drugs

Drug companies say the government must help pay for new antibiotics people will rarely use. But without them, Australians may die.

  • Michael Smith

August

Professor Marnie Blewitt is developing a new XX, which is back by acting deputy director and laboratory head and Chief Executive Of at WEHI Ventures Dr Anne-Laure Puaux in Melbourne

How this research institute turned cancer success into a $66m VC fund

After banking $US325m from co-developing a blockbuster cancer drug, WEHI has begun making start-up investments seeking scientific breakthroughs from a new $66m fund.

  • Tess Bennett
The study findings should prompt physicians to be more cautious about prescribing the drug to people with a history of depression or suicide attempts.

Ozempic could be linked to suicidal thoughts

Novo Nordisk said it will work with regulators to monitor the safety of the medicines, including surveillance of data from ongoing studies and real-world use.

  • Naomi Kresge

This special paint could save lives from bushfires

New paint technology developed at UNSW to help fire-proof homes is a joint winner in the Higher Education Awards research commercialisation category.

  • Alexandra Cain
Swinburne University students on the job - taking part in Work Integrated Learning.  

Job-ready skills for the fast-changing workplace

The joint winners of the employability category embed career experience in study programs to give graduates an edge in the competitive job market.

  • Sian Powell

How medical research is failing women

For years, the process for developing and testing new drugs has focused disproportionately on male bodies — to the detriment of female patients.

  • Sarah Neville
Nature’s Care headquarters in Belrose, Sydney.

Nature’s Care sale docs in front of potential buyers; NBIOs due Sept 6

Although the company returned a $23.7 million operating profit in 2023, it has struggled under a heavy debt load and missed a $148 million debt payment last month.

  • Sarah Thompson, Kanika Sood and Emma Rapaport
Chemist Warehouse is expected to sell off part of its store network to convince the ACCC that the merger will not lead to higher prices for consumers.

Competition regulator delays $8.8b Chemist Warehouse deal approval

The ACCC is undertaking more analysis of the transaction, which would merge the pharmacy giant into Sigma Healthcare. A decision won’t be made until October.

  • Michael Smith
Nature’s Care was Australia’s third-largest vitamins company.

Houlihan Lokey tapped for Nature’s Care sale

Street Talk can reveal receivers BDO Australia called in Houlihan Lokey to kick off a sale process.

  • Sarah Thompson, Kanika Sood and Emma Rapaport
Advertisement
Novo Nordisk Australia boss Cem Ozenc says there is enthusiasm in government for Wegovy.

Ozempic maker wants taxpayer subsidy for new Wegovy drug

Danish pharmaceutical giant Novo Nordisk pulled in more than $600 million from Australia last year but reported just $17 million in profit here.

  • Nick Bonyhady
Wegovy is launching in Australia two years after being approved by regulators.

Next blockbuster weight-loss drug to launch in Australia this month

Novo Nordisk’s Wegovy is about to go on sale here, avoiding the prospect of a supply disaster when compounded Ozempic is banned.

  • Updated
  • Nick Bonyhady

July

Nasal viagra biotech launches capital raising, Alpine on ticket

Street Talk understands sole lead manager Alpine Capital was seeking bids at 73¢ per share on Monday morning.

  • Sarah Thompson, Kanika Sood and Emma Rapaport
Research suggests testosterone can improve your midlife health and relationships.

Why testosterone is a wonder drug for men and women over 50

More than just a male sex hormone, it can be the foundation for a healthy lifestyle – and the Olympics is about to put its powers under the spotlight again.

  • Hattie Garlick
Kim Arculli Walker is still making up her mind on whether NAD+ is a fad or the real deal.

Want to live to 100? Maybe try this new supplement

Can the latest longevity pill help restore your youthful vigour and avoid age-related disease? Be warned: there may be risks.

  • David Cox

Original URL: https://www.afr.com/topic/pharmaceuticals-hnn